Jenburkt Pharmaceuticals Limited (BOM:524731)
India · Delayed Price · Currency is INR 1,156.90
-17.65 (-1.50%)
At close: Jun 16, 2026
Jenburkt Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 1,687 | 1,517 | 1,420 | 1,367 | 1,240 |
Other Revenue | - | - | 0 | - | - |
| 1,687 | 1,517 | 1,420 | 1,367 | 1,240 | |
Revenue Growth (YoY) | 11.24% | 6.85% | 3.82% | 10.30% | 13.44% |
Cost of Revenue | 323.26 | 308.3 | 313.42 | 338.6 | 321.51 |
Gross Profit | 1,364 | 1,209 | 1,106 | 1,029 | 918.3 |
Selling, General & Admin | 498.82 | 455.36 | 424.89 | 388.07 | 364.91 |
Other Operating Expenses | 427.93 | 349.14 | 350.1 | 336.35 | 280.04 |
Operating Expenses | 957.82 | 831.78 | 798.38 | 747.01 | 663.93 |
Operating Income | 406.33 | 376.84 | 307.87 | 281.88 | 254.37 |
Interest Expense | -4.62 | -3.8 | -2.3 | -3 | -3.48 |
Interest & Investment Income | - | 53.5 | 41.8 | 40.65 | 44.04 |
Currency Exchange Gain (Loss) | - | 4.93 | 3.32 | 7.6 | 2.45 |
Other Non Operating Income (Expenses) | 102.99 | -0.73 | -0.41 | 0.46 | -0.87 |
EBT Excluding Unusual Items | 504.7 | 430.74 | 350.28 | 327.59 | 296.51 |
Gain (Loss) on Sale of Investments | - | 8.58 | 1.33 | 0.04 | 0.02 |
Gain (Loss) on Sale of Assets | - | - | - | - | 1.84 |
Other Unusual Items | -39.51 | - | - | - | - |
Pretax Income | 465.19 | 439.33 | 351.76 | 328.65 | 298.71 |
Income Tax Expense | 117.83 | 118.72 | 91.99 | 82.58 | 75.74 |
Net Income | 347.36 | 320.61 | 259.77 | 246.07 | 222.97 |
Net Income to Common | 347.36 | 320.61 | 259.77 | 246.07 | 222.97 |
Net Income Growth | 8.34% | 23.42% | 5.57% | 10.36% | 35.12% |
Shares Outstanding (Basic) | 4 | 4 | 4 | 5 | 5 |
Shares Outstanding (Diluted) | 4 | 4 | 4 | 5 | 5 |
Shares Change (YoY) | -0.00% | - | -3.34% | -0.52% | - |
EPS (Basic) | 78.71 | 72.65 | 58.86 | 53.90 | 48.58 |
EPS (Diluted) | 78.71 | 72.65 | 58.86 | 53.90 | 48.58 |
EPS Growth | 8.35% | 23.42% | 9.21% | 10.93% | 35.12% |
Free Cash Flow | 128.05 | 81.92 | 55.7 | 149.48 | 62.17 |
Free Cash Flow Per Share | 29.02 | 18.56 | 12.62 | 32.74 | 13.55 |
Dividend Per Share | 20.700 | 18.000 | 15.300 | 14.400 | 12.000 |
Dividend Growth | 15.00% | 17.65% | 6.25% | 20.00% | 17.65% |
Gross Margin | 80.84% | 79.68% | 77.92% | 75.24% | 74.07% |
Operating Margin | 24.08% | 24.84% | 21.69% | 20.61% | 20.52% |
Profit Margin | 20.59% | 21.14% | 18.30% | 17.99% | 17.98% |
Free Cash Flow Margin | 7.59% | 5.40% | 3.92% | 10.93% | 5.01% |
EBITDA | 437.4 | 397.4 | 324.26 | 298.93 | 267.14 |
EBITDA Margin | 25.92% | 26.20% | 22.84% | 21.86% | 21.55% |
D&A For EBITDA | 31.08 | 20.56 | 16.4 | 17.05 | 12.77 |
EBIT | 406.33 | 376.84 | 307.87 | 281.88 | 254.37 |
EBIT Margin | 24.08% | 24.84% | 21.69% | 20.61% | 20.52% |
Effective Tax Rate | 25.33% | 27.02% | 26.15% | 25.13% | 25.36% |
Revenue as Reported | 1,790 | 1,584 | 1,466 | 1,419 | 1,289 |